Modern Diagnostic schedules board meeting on Sep 3 to approve AGM notice

0 min read | Published on 26 Aug 2026, 05:05 PM |Updated on 26 Aug 2026, 05:05 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Board meeting scheduled for September 3, 2026
Agenda includes AGM notice and Director Report approval
Scrutinizer appointment to be considered
Intimation filed under SEBI LODR Regulation 29

*this image is generated using AI for illustrative purposes only.

Modern Diagnostic & Research Centre Limited has scheduled a board meeting for Thursday, September 3, 2026. The session will focus on administrative approvals, including the Annual General Meeting (AGM) notice.

The company issued the intimation under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Priyanshu Yadav, Company Secretary & Compliance Officer, signed the disclosure dated August 26, 2026.

Agenda Items

The board will consider the following key matters:

Appointment of Scrutinizer
Approval of Director Report
Approval of AGM notice
Other businesses

This meeting is part of the standard pre-AGM procedural requirements for listed entities.

Historical Stock Returns for Modern Diagnostic & Research Centre

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	+6.25%	-1.92%	-35.44%	0.0%	0.0%

What specific financial metrics or strategic initiatives are expected to be highlighted in the upcoming Director Report?

How might the appointment of the Scrutinizer influence the transparency and efficiency of the AGM voting process for shareholders?

Are there any anticipated changes to the board composition or executive compensation that may be discussed under 'Other businesses'?

Modern Diagnostic & Research Centre

View Company Insights

View All News

Modern Diagnostic FY26 net profit falls 42% to ₹525.33 lakh

1 min read | Published on 29 May 2026, 03:49 PM |Updated on 29 May 2026, 04:12 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Modern Diagnostic and Research Centre Limited reported a 42% decline in net profit to ₹525.33 lakh for FY26, despite a 7% increase in revenue to ₹8,311.06 lakh. Total expenses rose to ₹7,814.58 lakh, impacting profitability. The company utilized ₹1,571.62 lakh of its ₹3,689.28 lakh IPO proceeds for capital expenditure and working capital. Gupta Aiyer & Co issued an unmodified opinion on the audited results.

*this image is generated using AI for illustrative purposes only.

Modern Diagnostic and Research Centre Limited reported a 42% decline in net profit to ₹525.33 lakh for the year ended March 31, 2026, down from ₹900.79 lakh in the previous year. Revenue from operations rose 7% to ₹8,311.06 lakh from ₹7,794.54 lakh in FY25. The company’s board approved the audited financial results on May 29, 2026.

The diagnostic services provider listed on the BSE SME platform on January 7, 2026, raising ₹3,689.28 lakh through an initial public offering (IPO). The proceeds were earmarked for capital expenditure, working capital requirements, and repayment of borrowings. As of March 31, 2026, the company had utilized ₹1,571.62 lakh of the IPO proceeds, leaving ₹1,744.89 lakh unutilized.

Total expenses for FY26 increased to ₹7,814.58 lakh from ₹6,593.49 lakh in the prior year, driven by higher costs of materials, employee benefits, and finance costs. The company’s basic earnings per share (EPS) stood at ₹3.48 for FY26, compared to ₹8.19 in the previous year.

Financial Performance

Particulars	Year Ended Mar 31, 2026 (₹ in Lacs)	Year Ended Mar 31, 2025 (₹ in Lacs)
Revenue from operations	8,311.06	7,794.54
Total Income	8,413.71	7,880.46
Total Expenses	7,814.58	6,593.49
Profit for the period	525.33	900.79
Basic EPS (₹)	3.48	8.19

IPO Proceeds Utilisation

Item Head	Proposed Utilisation (₹ in Lacs)	Utilisation upto Mar 31, 2026 (₹ in Lacs)
Capital Expenditure	2,068.95	646.28
Working Capital Requirement	800.00	492.01
Repayment of Borrowings	100.00	100.00
General Corporate Purpose	333.33	333.33
Total	3,302.28	1,571.62

Auditor’s Report

Gupta Aiyer & Co, Chartered Accountants, issued an unmodified opinion on the audited financial results. The auditors identified the utilization of IPO proceeds as a key audit matter, noting that the funds were utilized for the purposes stated in the prospectus, with temporary deployment of unutilized funds in compliance with regulatory requirements. The auditors also confirmed the adequacy and operating effectiveness of the company’s internal financial controls over financial reporting.

Historical Stock Returns for Modern Diagnostic & Research Centre